Open house drug rebate agreements Lanthanum(III)-carbonate, ATC V03AE03
Original notice title
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Lanthan(III)-carbonat, ATC V03AE03
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
20 / 100
Risk factors
No estimated value or guaranteed volume; revenue depends on actual usage and discount rates
Automatic termination if a competing nationwide or state-level rebate contract is concluded for the same active substan...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Jun 2028
- Non-exclusive pharmaceutical rebate agreements for Lanthanum(III)-carbonate (ATC V03AE03)
- Supply of pharmaceutical products to AOK Bayern at discounted prices
Show full summary
Non-exclusive open-house model for pharmaceutical rebate agreements on Lanthanum(III) carbonate (ATC V03AE03) with AOK Bayern. Eligible pharmaceutical companies can join at any time until 03 May 2028, with contracts running from 01 July 2026 to 30 June 2028. No estimated value provided. Submission is either in writing (two copies) or electronically with qualified electronic signature. Only self-declaration of reliability is required for eligibility. The contract is non-negotiable and non-exclusive.
Risks
No estimated value or guaranteed volume; revenue depends on actual usage and discount rates
Automatic termination if a competing nationwide or state-level rebate contract is concluded for the same active substan...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Eligibility
- Only pharmaceutical companies are eligible
Administrative
- Submission of signed self-declaration of reliability
- Submission of signed contract and annex 'Festlegung der vertragsgegenständlichen Arzneimittel'
Requirements may be incomplete.
Award Criteria
Lot 1
Buyer
Location
München, DEU
Website
Buyer profile
Identifier
DE811695320
Activity
Health
Lots (1)
LOT-0001
Open house drug rebate agreements Lanthanum(III)-carbonate, ATC V03AE03
Open-house model for non-exclusive rebate agreements on pharmaceutical products containing Lanthanum(III)-carbonate (ATC V03AE03). Contracts available to all interested pharmaceutical companies meeting eligibility criteria. No selection process; all eligible companies can join. Duration from 01 July 2026 to 30 June 2028. Submission deadlines for joining: 3rd of each month for next month start, or later. Contracts may be terminated with one month's notice.
Location
Duration
Category
Award Criteria
Deadline
Award details
No award criteria as this is an open-house model without selection
contracts are offered to all eligible companies.
Value note
Show original TED data
Original lot title
Open house Arzneimittelrabattverträge Lanthan(III)-carbonat, ATC V03AE03
Original TED description
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich! BITTE BEACHTEN SIE: Die FRIST für einen Vertragsschluss zum nächsten Monatsersten endet jeweils am DRITTEN des Vormonats.
Procurement Details
- Publication date
- 17 May 2026
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 337536-2026
Documents (2)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
20 / 100
Risk factors
No estimated value or guaranteed volume; revenue depends on actual usage and discount rates
Automatic termination if a competing nationwide or state-level rebate contract is concluded for the same active substan...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications